Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY21 results · Jan–Mar 2021
Indoco Remedies reported revenue from operations of ₹305.14 crore (up 12.2% from Q4 FY20) and net profit of ₹25.00 crore (up 366.4% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 305.14 | 271.99 | +12.2% | 332.29 | −8.2% |
| Other income | 1.98 | 0.50 | +296.0% | 0.36 | +450.0% |
| Total income | 307.12 | 272.49 | +12.7% | 332.65 | −7.7% |
| Profit before tax | 33.56 | 7.76 | +332.5% | 37.63 | −10.8% |
| Net profit for the period | 25.00 | 5.36 | +366.4% | 25.36 | −1.4% |
| EPS, basic (₹) | 2.71 | 0.58 | +367.2% | 2.75 | −1.5% |
| Net margin (%) | 8.2 | 2.0 | 7.6 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 304.85 | 272.02 | +12.1% | 331.94 | −8.2% |
| Other income | 1.97 | 0.49 | +302.0% | 0.37 | +432.4% |
| Total income | 306.82 | 272.51 | +12.6% | 332.31 | −7.7% |
| Profit before tax | 33.45 | 7.80 | +328.8% | 37.42 | −10.6% |
| Net profit for the period | 24.91 | 5.40 | +361.3% | 25.14 | −0.9% |
| EPS, basic (₹) | 2.70 | 0.59 | +357.6% | 2.73 | −1.1% |
| Net margin (%) | 8.2 | 2.0 | 7.6 |
Consolidated
- Filed with BSE
- 25 May 2021, 13:17 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2021, 13:17 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE